Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology O-39 CLINICAL CHARACTERISTICS AND OUTCOME OF DRUG-INDUCED LIVER INJURY DUE TO AN...
Journal Information
Vol. 28. Issue S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(March 2023)
Share
Share
Download PDF
More article options
Vol. 28. Issue S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(March 2023)
Full text access
O-39 CLINICAL CHARACTERISTICS AND OUTCOME OF DRUG-INDUCED LIVER INJURY DUE TO ANTINEOPLASTIC AND BIOLOGICAL AGENTS
Visits
166
Fernando Bessone1, Nelia Hernandez2, Raymundo Parana3, Maria Isabel Schinoni3, Manuel Mendizabal4, Adriana Sanchez2, Vinicius Nunes3, Ezequiel Ridruejo5, Daniela Schiodi2, Eduardo Fassio6, Hugo Tanno1, Norberto Tamagnone1, Martin Tagle7, Pedro Montes8, I Medina-Caliz9, Mercedes Robles-Díaz9, Aida Ortega-Alonso9, Miren García-Cortes9, Hao Niu9, Ismael Alvarez-Alvarez9..., Rocío Romero-Flores9, M Isabel Lucena9, Raul J Andrade9Ver más
1 Provincial Hospital of Centenario, University of Rosario School of Medicine, Rosario, Argentina
2 Gastroenterology Clinic, Clinic Hospital, University of Republic, Montevideo, Uruguay
3 Universitary Prof. Edgard Santos-UFBA, Salvador, Brazil
4 Austral University Hospital, Pilar, Argentina
5 Center for Medical Education and Clinical Research, Buenos Aires, Argentina
6 Alejandro Posadas Hospital, Buenos Aires, Argentina
7 Anglo American Clinic, Lima, Perú
8 Daniel Alcides Carrión National Hospital, Callao, Perú
9 UGC Digestive System and Clinical Pharmacology, Virgen de la Victoria University Hospital, Biomedical Research Institute de Málaga-IBIMA, Málaga University, Málaga; CIBERehd, Madrid, Spain
Ver más
This item has received
Article information
Special issue
This article is part of special issue:
Vol. 28. Issue S1

Abstracts of the 2022 Annual Meeting of the ALEH

More info
Introduction and Objectives

Idiosyncratic drug-induced liver injury (DILI) caused by antineoplastic and biological agents is an emerging clinical burden in oncologic patients. However, clinical characteristics of DILI due to these drugs remain poorly understood. This study aimed to assess the clinical presentation and outcome of DILI caused by antineoplastic and biological agents in patients enrolled in the prospective Spanish and Latin American DILI registries.

Materials and Methods

Information from well-vetted DILI cases caused by antineoplastic and biological agents enrolled in the Spanish DILI Registry (n=38) and the LATINDILI Network (n=33) since their establishment in 2022 was retrieved. Demographics, clinical characteristics, laboratory findings and outcome were analyzed through descriptive statistics.

Results

Overall, DILI patients were aged 61±17 years, with Latin American patients slightly younger than Spanish cases (64 vs. 56; p=0.053) and were predominantly men (66%). Novel therapies such as Protein Kinase Inhibitors represented 14% of cases, while Immune Checkpoint Inhibitors caused 6% of DILI cases. Hepatocellular damage predominated (79%), while 12% had a cholestatic injury. Nearly 70% of patients developed jaundice, and 49% were hospitalized. Alanine and aspartate aminotransferase were highly increased (median values 13 and 11 times above the upper limit of normal (ULN), respectively), while alkaline phosphatase showed modest elevations (1.3 times ULN). Total bilirubin was elevated by a median of 3.7-fold ULN. Most of the patients coursed with a moderate injury (46%), and 15% developed severe liver damage. Four Spanish cases, and one from Latin America, had liver-related death (p=0.018). There were no chronic DILI cases, and 71% of patients resolved spontaneously.

Conclusions

DILI, due to antineoplastic and biological agents, was more common in men, caused a hepatocellular injury, and usually coursed as a moderate-to-severe liver injury. Latin American cases were slightly younger, while the mortality rate was higher among Spanish DILI patients.

Full text is only aviable in PDF
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos